Sponsored Content
Initial evidence suggests a role for synbiotic supplements in managing digestive discomfort and enhancing behavioral wellbeing in autistic children
8 Apr 2025
Evidence from a clinical study deepens insight into role of the gut-brain axis, marking progress towards a more holistic strategy for managing gastrointestinal (GI), irritability and anxiety-related symptoms in autistic children with synbiotics, either alone or in combination with gut-directed hypnotherapy (GDH).
A new study from the University of Queensland, published in the Journal of Autism and Developmental Disorders, has revealed that a combined intervention of a synbiotic and gut-directed hypnotherapy (GDH) significantly reduces gastrointestinal (GI) discomfort, irritability and anxiety symptoms in autistic children. The research provides new insight into the microbiome-gut-brain (MGB) axis and its role in autism, and creates an opportunity for supplement manufacturers to tap into demand for reliable, safe and effective solutions for increasing the standard of care for autistic children with comorbid gut symptoms.
Alterations in microbiota composition have long been associated with both autism spectrum disorder (ASD) and disorders of gut-brain interaction (DGBI), which are more common in children with autism, and are typically associated with stereotypical behavior, such as hyperactivity and anxiety.
Measuring success: study method, objectives and key results
The randomized pilot study involved 40 children diagnosed with ASD aged five to ten years. It compared the effects of synbiotics alone (SYN group) and synbiotics combined with GDH (COM group). Probiotics and prebiotics have both shown efficacy in improving GI and behavioral symptoms in autistic children, along with GDH, which is a commonly used treatment that aims to manage anxiety symptoms and normalize signals between the gut and the brain using relaxation techniques, guided imagery, and suggestive storytelling.
As a primary end point, the study set out to assess changes in GI scores evaluating common symptoms such as constipation or diarrhea, over a 12-week intervention period with a follow-up at 24 weeks. Interestingly, both groups exhibited significant reductions in GI symptoms post-intervention and at follow-up, with no superiority of the COM treatment over the SYN treatment.
A secondary objective was set to observe improvements in behavioral and anxiety symptoms. The SYN group showed significantly improved scores for hyperactivity and stereotypical behavior. The COM group also showed improvements in these areas, in addition to irritability, social withdrawal, anxiety and inappropriate speech when compared to baseline.
The COM group also maintained significant reductions in GI pain scores at follow-up, suggesting lasting benefits of GDH when combined with synbiotic supplementation.
Changes in gut microbiome composition were also assessed as an exploratory benefit. These were observed across both groups, and included increases in Bifidobacterium animalis and Dialister, indicating a potential link between microbiome modulation and symptom improvement.
Together, these data suggest that synbiotics with or without GDH can help to support standard care for autistic children who also suffer from gut symptoms.

The opportunity
“The study contributes to a growing body of evidence suggesting that modulating the gut microbiome can have far-reaching effects beyond digestion, potentially influencing GI comfort, anxiety and behavior in autistic children,” said PD Dr Robert E Steinert, Principal Scientist at dsm-firmenich. “It represents a promising step towards a more holistic approach for managing symptoms in autistic children, and more widely, underscores the wider importance of the gut-brain axis in overall well-being. There is a clear opportunity here for supplement brands to expand their offerings with safe and targeted solutions that support higher standards of care for autistic children with comorbid gut symptoms.”
Powerful ingredients: Humiome® biotics
The study used biotics supplied by dsm-firmenich from its Humiome® portfolio, with the products chosen for their proven capability to improve gut health and supporting the gut-brain axis. The biotics supplied included a blend of Humiome® L. rhamnosus GG (ATCC 53103), Humiome® L. plantarum DSM 34532 (formerly known as L. plantarum TIFN101), Humiome® B. lactis DSM 32269 and B. longum DSM 32946.
Read more about dsm-firmenich’s commitment to advancing science to elevate global health here: https://www.dsm-firmenich.com/en/businesses/health-nutrition-care/segments/dietary-supplements/health-from-the-gut.html
Related news

Be Active! GELITA presents collagen peptides for active aging, beauty and ingredient delivery at Vitafoods Europe 2025, booth 3J104
7 Apr 2025
March 2025 – ‘Be Active!’ will be the theme on GELITA’s booth at Vitafoods Europe 2025, providing an inspiring backdrop for discussing collagen-powered concepts for active beauty and active aging. GELITA will demonstrate how man...
Read more
Discover the first & only third party certified grass-fed collagen on the market
7 Apr 2025
Certified SOLUGEL® grass-fed collagen peptides are PB Leiner’s solution for pure and sustainably sourced collagen peptide supplements. The cattle are raised outdoors, ensuring highest standards of animal well-being, and they are free fro...
Read more
dsm-firmenich wins patent lawsuit protecting algal oil innovations
7 Apr 2025
dsm-firmenich, the leading innovator in health, nutrition, and beauty, today announces it has won its patent infringement case against Canada-based Mara Renewables Corporation and its UK subsidiary, Algal Omega-3 Ltd (together "Mara/AO3"). Th...
Read more
dsm-firmenich launches Maxiren®EVO: A revolutionary coagulant enzyme for enhanced cheese texture, taste, yield, and functionality
7 Apr 2025
dsm-firmenich, innovator in nutrition, health, and beauty, introduces Maxiren®EVO, the latest breakthrough in coagulant enzymes designed to transform cheese production. Maxiren®EVO is engineered with cutting-edge fermentation technology and tar...
Read more
Hoogwegt: Your Partner in Dairy Ingredients for the Chocolate Industry
7 Apr 2025
The chocolate industry is constantly evolving, with manufacturers facing the challenge of delivering high-quality products that meet both consumer demands and sustainability goals. Hoogwegt plays a key role in this landscape by offering a wide range of...
Read more
Improving Decision-Making in the Nutraceutical Industry Through Automation
4 Apr 2025
Explore they ways in which automation can help your nutraceutical companies increase precision and efficiency.
Read more
Rioja Nature Pharma obtains Friend of the Sea certification
1 Apr 2025
Rioja
Nature Pharma takes another step forward in its commitment to excellence and
the environment by obtaining Friend of the Sea certification for its Omega-3
EPA and Omega-3 DHA softgel fish oil food supplement manufacturing lines.

New high-CBD raw material brings opportunities for the nutraceuticals industry
26 Mar 2025
A new high-CBD raw material is available to the nutraceuticals industry. Bedrocan, an experienced cannabis cultivator, explains why non-hemp CBD of consistent content is an advantage.
Read more
Rioja Nature Pharma incorporates Sulphoraphan Smart, an innovative compound patented by Ingredalia, to its catalogue of ingredients.
25 Mar 2025
Sulforaphane is the active ingredient of broccoli that makes this vegetable a superfood, as it activates the cellular defence against inflammation and oxidation. However, its synthesis and absorption is not always correct, as it is degraded before reac...
Read more
Faster, higher, better – Unlock the Power of Mineral Salts in Sports Nutrition
20 Mar 2025
Calcium, Iron, Magnesium, and Zinc fuel athletes' energy and recovery. German manufacturer Dr. Paul Lohmann® provides high-quality Mineral Salts that support peak athletic performance.
Read more